DC Bead embolic drug-eluting bead: Clinical application in the locoregional treatment of tumours

Expert Opinion on Drug Delivery

Volumn 8, Issue 2, 2011, Pages 153-169

  Lewis, Andrew L ^a   Holden, Rachel R ^a  

^a BIOCOMPATIBLES UK LTD   (United Kingdom)

Author keywords

DC Bead; doxorubicin; hepatocellular carcinoma; irinotecan; transarterial chemoembolisation

Indexed keywords

2 ACRYLAMIDO 2 METHYLPROPANESULFONATE SODIUM; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; BEVACIZUMAB; CETUXIMAB; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GELATIN; GELFOAM; GEMCITABINE; IODINATED POPPYSEED OIL; IRINOTECAN; MICROSPHERE; MICROSPHERE Y 90; MITOMYCIN C; OXALIPLATIN; PLACEBO; POLYACRYLIC ACID; POLYMER; POLYPHOSPHAZENE; POLYVINYL ALCOHOL; RADIOACTIVE MICROSPHERE; SORAFENIB; STARCH MICROSPHERE; SULFONIC ACID DERIVATIVE; SUNITINIB; TOPOTECAN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ALGORITHM; AREA UNDER THE CURVE; BILE DUCT CARCINOMA; BIOCOMPATIBILITY; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CANCER THERAPY; CHEMOEMBOLIZATION; COLORECTAL CANCER; CONTROLLED DRUG RELEASE; CRYOABLATION; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; EMBOLIC DRUG ELUTING BEAD; FEVER; HUMAN; HYDROGEL; LIVER CANCER; LIVER CELL CARCINOMA; LIVER METASTASIS; LIVER TRANSPLANTATION; MAXIMUM PLASMA CONCENTRATION; MICROWAVE THERAPY; MULTICENTER STUDY (TOPIC); NAUSEA AND VOMITING; NONHUMAN; OVERALL SURVIVAL; PERCUTANEOUS ETHANOL INJECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTEMBOLISATION SYNDROME; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SUSTAINED DRUG RELEASE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; INFUSIONS, INTRA-ARTERIAL; MICROSPHERES; NANOMEDICINE; NANOSPHERES; NEOPLASMS;

EID: 79251506375     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2011.545388     Document Type: Review

References (73)

1. Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, Cancer incidence and mortality worldwide: IARC CancerBased No 10 [Internet]. In. Lyon: International Agency for Research on Cancer; 2010
2. Cancer mortality incidence in the UK 2005-7. In: UK Office of National Statistics, ed.; 2010
3. Venugopalan P, Jain S, Sankar S, et al. pH-sensitive liposomes: mechanism of triggered release to drug and gene delivery prospects. Pharmazie 2002;57:659-71
4. Poon RT, Borys N. Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opin Pharmacother 2009;10:333-43
5. Coulter A. The status of photodynamic therapy research: an overview of current and future cancer clinical treatments. J Clin Laser Med Surg 1990;8:2-11
6. Goodwin SC, Bittner CA, Peterson CL, Wong G. Single-dose toxicity study of hepatic intra-arterial infusion of doxorubicin coupled to a novel magnetically targeted drug carrier. Toxicol Sci 2001;60:177-83
7. Perry J, Chambers A, Spithoff K, Laperriere N. Gliadel wafers in the treatment of malignant glioma: a systematic review. Curr Oncol 2007;14:189-94
8. Elstad NL, Fowers KD. OncoGel (ReGel/paclitaxel)-clinical applications for a novel paclitaxel delivery system. Adv Drug Deliv Rev 2009;61:785-94
9. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9
10. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71
11. Kerr DJ. Microparticulate drug delivery systems as an adjunct to cancer treatment. Cancer Drug Deliv 1987;4:55-61
12. Lewis AL. DC Bead(TM): a major development in the toolbox for the interventional oncologist. Expert Rev Med Devices 2009;6:389-400
13. Lewis AL, Gonzalez MV, Lloyd AW, et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol 2006;17:335-42
14. Taylor RR, Tang Y, Gonzalez MV, et al. Irinotecan drug eluting beads for use in chemoembolization: in vitro and in vivo evaluation of drug release properties. Eur J Pharm Sci 2007;30:7-14
15. Satake M, Uchida H, Arai Y, et al. Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan. Cardiovasc Intervent Radiol 2008;31:756-61
16. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007;30:6-25
17. Bank WO, Kerber CW. Gelfoam embolization: a simplified technique. AJR Am J Roentgenol 1979;132:299-301
18. Erichsen C, Bolmsjo M, Hugander A, Jonsson PE. Blockage of the hepatic-artery blood flow by biodegradable microspheres (Spherex) combined with local hyperthermia in the treatment of experimental liver tumors in rats. J Cancer Res Clin Oncol 1985;109:38-41
19. Siskin GP, Dowling K, Virmani R, et al. Pathologic evaluation of a spherical polyvinyl alcohol embolic agent in a porcine renal model. J Vasc Interv Radiol 2003;14:89-98
20. Laurent A, Beaujeux R, Wassef M, et al. Trisacryl gelatin microspheres for therapeutic embolization, I: development and in vitro evaluation. AJNR Am J Neuroradiol 1996;17:533-40
21. Stampfl S, Bellemann N, Stampfl U, et al. Arterial distribution characteristics of Embozene particles and comparison with other spherical embolic agents in the porcine acute embolization model. J Vasc Interv Radiol 2009;20:1597-607
22. Seki A, Hori S, Kobayashi K, Narumiya S. Transcatheter arterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for 135 hepatocellular carcinoma patients: single-center experience. Cardiovasc Intervent Radiol 7 Sept 2010. [Epub ahead of print]
23. Mulcahy MF, Lewandowski RJ, Ibrahim SM, et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer 2009;115:1849-58
24. Ibrahim SM, Nikolaidis P, Miller FH, et al. Radiologic findings following Y90 radioembolization for primary liver malignancies. Abdom Imaging 2009;34:566-81
25. Di Maio M, Daniele B, Perrone F. Targeted therapies: role of sorafenib in HCC patients with compromised liver function. Nat Rev Clin Oncol 2009;6:505-6
26. Lewis AL, Gonzalez MV, Leppard SW, et al. Doxorubicin eluting beads-1: effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med 2007;18:1691-9
27. Gonzalez MV, Tang Y, Phillips GJ, et al. Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro: in-vivo correlation. J Mater Sci Mater Med 2007;19:767-75
28. Tang Y, Czuczman PR, Chung ST, Lewis AL. Preservation of the active lactone form of irinotecan using drug eluting beads for the treatment of colorectal cancer metastases. J Control Release 2008;127:70-8
29. Kaiser J, Thiesen J, Kramer I. Stability of irinotecan-loaded drug eluting beads (DC Bead) used for transarterial chemoembolization. J Oncol Pharm Pract 2009;16:53-61
30. Lewis AL, Taylor RR, Hall B, et al. Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol 2006;17:1335-43
31. Hong K, Khwaja A, Liapi E, et al. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006;12:2563-7
32. Rao P, Pascale F, Seck A, et al. Evaluation des modes dadministration dirinotecan sur modèles VX2 lapin: étude de pharmacocinetique et réponse tumorale. J Radiol 2009;90:1394
33. Namur J, Citron SJ, Dupuis M, et al. Diffusion of doxorubicin from drug eluting beads and tissular changes after embolisation of hepatocellular carcinoma [abstract 156]. J Vasc Interv Radiol 2009;20:S61
34. Baylatry M-T, Pelage JP, Lacombe P, et al. Plasmatic and lung concentrations after irinotecan-eluting beads (DEBIRI) embolization of pulmonary artery alone vs. combined with bronchial artery embolization in a sheep model. In: CIRSE 2010; 2010; Valencia; 2010. p. 333
35. Eyol E, Boleij A, Taylor RR, et al. Chemoembolisation of rat colorectal liver metastases with drug eluting beads loaded with irinotecan or doxorubicin. Clin Exp Metastasis 2008;25:273-82
36. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010;30:61-74
37. Aloia TA, Adam R, Samuel D, et al. A decision analysis model identifies the interval of efficacy for transarterial chemoembolization (TACE) in cirrhotic patients with hepatocellular carcinoma awaiting liver transplantation. J Gastrointest Surg 2007;11:1328-32
38. Dhanasekaran R, Kooby DA, Staley CA, et al. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study. HPB (Oxford) 2010;12:174-80
39. Kettenbach J, Stadler A, Katzler IV, et al. Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 2008;31:468-76
40. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010;33:41-52
41. Malagari K, Alexopoulou E, Chatzimichail K, et al. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead. Abdom Imaging 2008;33:512-9
42. Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010;33:541-51
43. Poon RTP, Tso WK, Pang RWC, et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 2007;5:1100-8
44. Reyes DK, Vossen JA, Kamel IR, et al. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J 2009;15:526-32
45. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474-81
46. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973;32:302-14
47. Moschouris H, Malagari K, Papadaki MG, et al. Contrast-enhanced ultrasonography of hepatocellular carcinoma after chemoembolisation using drug-eluting beads: a pilot study focused on sustained tumor necrosis. Cardiovasc Intervent Radiol 2010;33:1022-7
48. Ravaioli M, Grazi GL, Ercolani G, et al. Partial necrosis on hepatocellular carcinoma nodules facilitates tumor recurrence after liver transplantation. Transplantation 2004;78:1780-6
49. Nicolini A, Martinetti L, Crespi S, et al. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol 2010; 21:327-32
50. Lencioni R, Crocetti L, Petruzzi P, et al. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J Hepatol 2008;49:217-22
51. de Baere T, Deschamps F, Teriitheau C, et al. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 2008;19:855-61
52. Aliberti C, Benea G, Tilli M, Fiorentini G. Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-Release doxorubicin-eluting beads: preliminary results. Cardiovasc Intervent Radiol 2008;31:883-8
53. Geoghegan JG, Scheele J. Treatment of colorectal liver metastases. Br J Surg 1999;86:158-69
54. Vogl TJ, Gruber T, Balzer JO, et al. Repeated transarterial chemoembolization in the treatment of liver metastases of colorectal cancer: prospective study. Radiology 2009;250:281-9
55. Benoist S, Nordlinger B. Neoadjuvant treatment before resection of liver metastases. Eur J Surg Oncol 2007;33(Suppl 2):S35-41
56. Aliberti C, Tilli M, Benea G, Fiorentini G. Trans-arterial chemoembolization (TACE) of liver metastases from colorectal cancer using irinotecan-eluting beads: preliminary results. Anticancer Res 2006;26:3793-5
57. Bower M, Metzger T, Robbins K, et al. Surgical downstaging and neo-adjuvant therapy in metastatic colorectal carcinoma with irinotecan drug-eluting beads: a multi-institutional study. HPB (Oxford) 2010;12:31-6
58. Fiorentini G, Aliberti C, Turrisi G, et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In Vivo 2007;21:1085-92
59. Martin RC, Joshi J, Robbins K, et al. Transarterial chemoembolization of metastatic colorectal carcinoma with Drug-eluting beads, irinotecan (DEBIRI): multi-institutional registry. J Oncol 2009;2009:539795
60. Martin RC, Robbins K, Metzger T, et al. Hepatic intra-arterial injection of irinotecan eluting beads in unresectable colorectal liver metastatic refractory to standard systemic chemotherapy: results ofmulit-institutional study [abstract 85]. Proc Gastrointestinal Cancers Symp 2009;15-17:152
61. Martin RC, Robbins K, Tomalty D, et al. Transarterial chemoembolisation (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol 2009;7:80
62. Fiorentini G, Aliberti C, Benea G, et al. Evaluation at 16 months of a phase III study comparing TACE-DC beads IRI loaded (DEBIRI) with FOLFIRI (CT) for patients with nonresectable colorectal cancer (CRC) liver metastases (LM). In: ASCO 2009 Gastrointestinal Cancers Symposium; 2009; Abstract 448, Jan 15-17, San Francisco, USA
63. Lewis A 2010. Drug-device combination products: delivery technologies and applications: Woodhead Publishing; Cambridge
64. Fiorentini G, Aliberti C, Montagnani F, et al. Trans-arterial chemoembolisation of metastatic colorectal carcinoma (MCRC) to the liver adopting polyvinyl alcohol microspheres loaded with irinotecan (DEBIRI(tm)) compared to FOLFIRI (CT): evaluation at two years of a phase III clinical trial [poster 588]. In: ESMO. Milan; 2010
65. Fiorentini G, Aliberti C, Del Conte A, et al. Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo 2009;23:131-7
66. Martin RC, Howard J, Tomalty D, et al. Toxicity of irinotecan-eluting beads in the treatment of hepatic malignancies: results of a multi-institutional registry. Cardiovasc Intervent Radiol 2010;33:960-6
67. Huppert PE. Chemoembolization using irinotecan eluting beads. In: CIRSE 2010; Presentation 2202.3; Valenica; 2010
68. Sharma KV, Dreher MR, Tang Y, et al. Development of 'imageable' beads for transcatheter embolotherapy. J Vasc Interv Radiol 2010;21:865-76
69. Forster REJ, Bowyer C, Lewis AL, et al. Controlled delivery of doxorubicin and rapamycin from embolisation microspheres to treat hepatocellular carcinoma. J Pharm Pharmacol 2008;28:A-24
70. Baltes S, Freund I, Lewis AL, et al. Doxorubicin and irinotecan eluting beads for treatment of glioma-a pilot study in a rat model. J Mater Sci Mater Med 2010;21:1393-402
71. Vinchon-Petit S, Jarnet D, Michalak S, et al. Local implantation of doxorubicin drug eluting beads in rat glioma. Int J Pharm 2010;402:184-9
72. Forster REJ, Small S, Tang Y, et al. Comparison of DC Bead-Irinotecan and DC Bead-Topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer. J Mater Sci Mater Med 2010;21:2683-90
73. Keese M, Gasimova L, Schwenke K, et al. Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer. Int J Cancer 2009;124:2701-8